Hallgeir Rui
Dr. Rui holds the position of Professor of Cancer Biology, Medical Oncology, and Pathology at Thomas Jefferson University, Philadelphia, PA, USA. He serves as the Scientific Director of the Jefferson Breast Care Center and is the Leader of Kimmel Cancer Center’s Biology of Breast Cancer Program. Dr. Rui has made key contributions to increased understanding of the prolactin-Jak-Stat signaling in breast cancer. Loss of active Stat5 is an independent marker of poor prognosis and also an independent predictive marker of resistance to antiestrogen therapy. Dr. Rui and his team have invented cutting-edge matrix assembly (CEMA), a patented high-density tissue arraying technology for high-throughput in situ biomarker studies. Dr. Rui is the PI of a Komen Promise Grant to classify breast cancer tumors based on expression of druggable target proteins for improved personalized cancer care, and includes a novel Bayesian adaptive Phase II clinical trial of a Parp-inhibitor in the neoadjuvant setting for triple-negative breast cancer. Ongoing work validates prolactin-humanized mice as a host for patient-derived breast cancer xenotransplants for more accurate predictive testing of anti-cancer drugs.
Abstracts this author is presenting: